Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C
Reinfection and Long Term Outcomes in Intravenous Drug Users (IVDUs) After Hepatitis C Treatment
The investigators will identify possible participants using our database of previously treated hepatitis c patients. The investigators will identify those who have documented evidence of current injecting drug use as a risk…
- Trial name
- NCT01329952
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- Pennine Acute Hospitals NHS Trust
Hepatitis C
EPIC: Evaluation of Pharmacy-based Identification and Treatment of HCV
The research project aims to understand how pharmacies can be involved in the identification and treatment of hepatitis C (hep C).
- Trial name
- EPIC (NCT05412017)
- Testing
- Hepatitis C Point of Care Testing and Treatment
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Cool Aid Community Health Centre
Hepatitis C, Chronic
A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation
The purpose of the study is to evaluate effect of steady-state (when the amount of drug administered (in a given time period is equal to the amount of drug eliminated in that same period) of simeprevir and daclatasvir on the…
- Trial name
- NCT01938625
- Testing
- Simeprevir, Daclatasvir, Ribavirin
- Where
- 6 sites in Germany, Poland and 1 more
- Volunteers
- 35 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C
TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients
The purpose of this study is to assess the safety and tolerability of TMC647055 both after increasing single oral doses from 100 mg up to maximum 3000 mg in fed conditions, and after multiple oral doses in fed conditions at…
- Trial name
- NCT01202825
- Testing
- TMC647055, TMC435
- Where
- Belgium
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C, Liver Cirrhosis
Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)
This is a Phase 3b, randomized, open-label, parallel-group, multi-center, multi-national study of low-dose maintenance Peg interferon alpha-2b (Peg-Intron®) in subjects with human immunodeficiency virus-hepatitis C virus…
- Conditions
- Hepatitis C, Liver Cirrhosis, HIV Infections
- Trial name
- NCT00381017
- Testing
- Peg interferon alpha-2b
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C, Genotype 1
Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation
This study seeks to assess the effectiveness, patient reported outcomes, work productivity and healthcare resource utilization of the interferon-free regimen of paritaprevir /ritonavir (r) - ombitasvir, ± dasabuvir ± ribavirin…
- Trial name
- HCV RWE (NCT02669940)
- Volunteers
- 158 people
- Sponsor
- AbbVie
Hepatitis C
Treatment of Hepatitis c by Using Direct-acting Antiviral
Patients with hepatitis c showed increased level of oxidative stress. Increased level of serum lipid peroxidation leads to the production of toxic mediators as malondialdehyde (MDA) which lead to disease progression.
- Trial name
- NCT05372874
- Testing
- Direct Acting Antivirals
- Volunteers
- 50 people
- Sponsor
- Tanta University
Indolent Lymphoma
Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma
We and other investigators have revealed an association between Hepatitis C virus (HCV) seropositivity and an increased risk of developing marginal zone B-cell lymphoma (MZ), lymphoplasmacytic lymphoma (LPL, also known as…
- Trial name
- NCT03261349
- Testing
- Ledipasvir and sofosbuvir
- Volunteers
- 21 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C
Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects
The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV gentotype-1 in chronically infected subjects and to further evaluate the safety profile of EDP239.
- Trial name
- NCT01856426
- Testing
- EDP239
- Where
- 5 sites in United States, Germany
- Volunteers
- 28 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Hepatitis C Virus (HCV)
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
The purpose of this study is to determine if 48 weeks of therapy with Peginterferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Peginterferon alfa-2a plus…
- Trial name
- BASIS (NCT01754974)
- Testing
- Peginterferon Lambda-1a, Ribavirin, Peginterferon alfa-2a
- Where
- 16 sites in Czechia, Mexico and 1 more
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients with liver cirrhosis.
- Trial name
- NCT02673489
- Testing
- DCV, SOF, RBV
- Where
- 19 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Obesity, Weight Loss
Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation
Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and has a grave prognosis. Obesity is an epidemic in the US.Patients with HCC and obesity are not candidates for liver transplantation, depriving…
- Conditions
- Obesity, Weight Loss, Body Weight, Hepatocellular Carcinoma
- Trial name
- NCT02935478
- Testing
- Embospheres Microspheres
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- St. Louis University
HIV, Hepatitis B
Pan-Viral Screening and Linkage to Care Among GBMSM and Trans Women in Spain
The World Health Organization (WHO) aims to eliminate viral hepatitis as a public health threat by 2030, with major reductions in hepatitis B and C incidence and mortality.
- Conditions
- HIV, Hepatitis B, Hepatitis C
- Trial name
- PAN-TESTATE (NCT07085715)
- Testing
- Online self-sampling testing strategy to enhance pan-viral testing (HBV, HCV, HIV)
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Fundació Institut Germans Trias i Pujol
Hepatitis C
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
The purpose of this study is to determine if treatment with Pegylated Interferon Lambda-1a, given in combination with Ribavirin and Daclatasvir for 24 weeks, is as safe and effective as the standard treatment with Pegylated…
- Trial name
- STRUCTURE (NCT01718158)
- Testing
- Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 444 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV
This is a 1:1 randomized double-blind Placebo-controlled moncenter Phase IV study to investigate whether a successful interferon-free treatment of HCV-infection with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in combination…
- Trial name
- NCT03003338
- Testing
- OBV/PTV/r and DSV
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- Hannover Medical School
Chronic Hepatitis C
A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study
This is a Phase IV, open label, single center study of OBV/PTV/r + DSV +/- RBV for 12 or 24 weeks for the treatment of chronic HCV-1 infection in a real world urban clinical setting.
- Trial name
- HEARTLAND (NCT03710252)
- Testing
- paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
- Volunteers
- 100 people
- Sponsor
- American Research Corporation
HCV
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
The purpose of this study is to assess the efficacy and safety of Ravidasvir in combination with Danoprevir/r and ribavirin(RBV) by sustain virologic response 12 (SVR12), in treatment-naive, non-cirrhotic, chronic hepatitis C…
- Trial name
- NCT03362814
- Testing
- Ravidasvir, Danoprevir, Ritonavir
- Where
- China
- Volunteers
- 425 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Hepatitis C
Occult HCV Infection After DAAD Treatment in Haemodialysis Patients
This research aims to evaluate the prevalence and predictors of Occult HCV among hemodialysis (HD) patients who achieved 24 weeks sustained virological response (SVR) after treatment with direct-acting antiviral agents (DAA) by…
- Trial name
- NCT04719338
- Testing
- presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Alexandria University
Hepatitis C, Hepatitis C Virus
A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C
This study seeks to evaluate the safety and efficacy of taking fluvastatin along with peginterferon alfa in previous partial responders with genotype 1 HCV.
- Trial name
- NCT00814606
- Testing
- Fluvastatin, Peginterferon alfa2a, ribavirin
- Sponsor
- University of Chicago
Chronic Hepatitis C, Liver Fibrosis
Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C
There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosis in rodents and limited…
- Trial name
- NCT00298714
- Testing
- Losartan
- Volunteers
- 20 people
- Sponsor
- Hospital Clinic of Barcelona
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.